Zobrazeno 1 - 10
of 92
pro vyhledávání: ''
Publikováno v:
Thrombosis Research. 196:510-515
Introduction On-treatment platelet aggregability represents the major form of functional assessment for patients treated with P2Y12 receptor antagonists, with “high” on-treatment platelet aggregability (HTPA) predicting thrombotic risk. However H
Autor:
Silvia Gabriela Sosa, Joan Antoni Gómez-Hospital, Angel Cequier, Josep Comín-Colet, Luis Teruel, Josep Gomez-Lara, Adrián Besteiro, Leslie Marisol Lugo, Rafael Romaguera, Ana Lucrecia Marcano, José Luis Ferreiro, Lara Fuentes, Montserrat Gracida, Gerard Roura
Publikováno v:
Thrombosis research. 196
Patients with heart failure (HF) display elevated levels of soluble fractalkine, a chemokine involved in inflammation processes, atherosclerosis and platelet activation. Further, fractalkine has been associated with reduced pharmacodynamic (PD) respo
Autor:
Emanuele Sagazio, Matteo Nardin, Francesco Tonon, Federica Negro, Rocco Gioscia, Nicolai Fierro, Roberta Rolla, Giuseppe De Luca, Patrizia Pergolini, Monica Verdoia
Publikováno v:
Thrombosis research. 196
Background The positive interaction of ticagrelor with the metabolism of adenosine has been claimed for the large antithrombotic and antiischemic benefits of this antiplatelet agent in acute coronary syndromes (ACS). Adenosine catabolism is regulated
Autor:
Sebastian Voicu, Patrick Henry, Stephane Manzo Silberman, Jean-Guillaume Dillinger, Claire Bal dit Sollier, Ludovic Drouet, Georgios Sideris, Alaa Saeed, Vincent Spagnoli
Publikováno v:
Thrombosis Research. 144:56-61
Background Despite dual antiplatelet treatment, major ischemic events are common following ST elevation myocardial infarction (STEMI). We aimed to assess high platelet reactivity on aspirin (HPR-aspirin) and its association with P2Y12i (HPR-P2Y12i) d
Autor:
Anna Komosa, Tatiana Mularek-Kubzdela, Michał Michalak, Andrzej Siniawski, Stefan Grajek, M Lesiak, Jadwiga Kowal, Jolanta M. Siller-Matula, Maciej Mączyński, S. Wiśniewski
Publikováno v:
Thrombosis Research. 138:49-54
Introduction Percutaneous coronary angioplasty (PCI) has become a routine treatment in symptomatic patients with coronary artery disease. The use of new generation drug eluting stents (DES) and dual antiplatelet therapy has significantly improved tre
Autor:
Brian A. Moser, Kenneth J. Winters, Joseph A. Jakubowski, Stefan James, David Erlinge, Patricia B. Brown, Dominick J. Angiolillo, Chunmei Zhou, David S. Small, Jurriën M. ten Berg
Publikováno v:
Thrombosis Research. 134:552-557
Introduction Patients treated with clopidogrel who have higher body size exhibit greater platelet reactivity than patients with lower body size. In a retrospective analysis of the FEATHER trial, we examined the relationship between platelet response
Autor:
Tomonori Akasaka, Hiroko Miyazaki, Michio Mizobe, Kentaro Oniki, Kazunori Morita, Yuichiro Arima, Hisao Ogawa, Kazuko Nakagawa, Seiji Hokimoto, Koichi Kaikita
Publikováno v:
Thrombosis Research. 134:72-77
The aim of this study was to examine the impact of CYP2C19 genotype on clinical outcome in coronary artery disease (CAD) patients with or without diabetes mellitus (DM).CYP2C19 polymorphism and DM are associated with increased risk of cardiovascular
Autor:
Michio Mizobe, Koichi Kaikita, Seiji Hokimoto, Kazuko Nakagawa, Tomonori Akasaka, Yuichiro Arima, Hisao Ogawa
Publikováno v:
Thrombosis Research. 133:599-605
The response to clopidogrel, and some kind of the drug interaction are multifactorial.We enrolled 174 consecutive patients and determined CYP2C19 genotypes, measured platelet aggregation, and assessed the relationship between CYP2C19 genotype and pla
Autor:
Róbert Gábor Kiss, István Préda, Sarolta Leé, Katarina Vargova, Andrea Kovacs, Anna Apró, Petra Gulácsi-Bárdos, Emese Toth-Zsamboki, Istvan Hizoh, Zsofia Sztupinszki, Zsófia Horváth
Publikováno v:
Thrombosis Research. 133:257-264
The benefit of adjusted antiplatelet therapy in patients with myocardial infarction after primary percutaneous coronary intervention is not well elucidated. We aimed to identify patients with high on treatment platelet reactivity and to gradually adj
Publikováno v:
Thrombosis Research. 132:e94-e98
Treatment with clopidogrel, a selective platelet P2Y12 receptor antagonist, reduces risk of recurrent ischemic events in patients with acute coronary syndrome (ACS), by limiting platelet aggregation and activation. Stable whole blood clot formation r